Senator Cortez Masto Grills RFK Jr. on Medicare Drug Prices and Cancer Drug Exemptions

Confronting Drug Price Exemptions

• 🎯 Senator Catherine Cortez Masto challenged HHS Secretary Robert F. Kennedy Jr. on Medicare drug price negotiations and exemptions benefiting Big Pharma.
• 💡 She accused Kennedy of supporting legislation that shields blockbuster cancer drugs like Keytruda from Medicare Part B negotiation.
• 💰 These exemptions mean drugs like Keytruda, costing up to $175,000 per year, continue to drain Medicare of billions and burden families.

Kennedy's Defense and Contradictions

• 💬 RFK Jr. claimed that Medicare negotiations under the Inflation Reduction Act (IRA) were "poorly structured" and could actually raise costs.
• ⚖️ Cortez Masto highlighted the contradiction between Kennedy's populist rhetoric against Big Pharma and his support for the "big beautiful bill" that grants exemptions.
• ❓ He struggled to explain why cancer drugs were specifically exempted from negotiation, stating he was "not sure of that provision."

Knowledge Gaps on Senior Costs

• ⚠️ Kennedy was unable to answer questions about projected Medicare Part D premium increases, which are expected to rise by $15 to $50 per month.
• 📈 He also did not know about the expected 11.6% increase in Medicare Part B premiums for 2026, one of the largest in decades.
• 👴 Cortez Masto emphasized that 23 million Medicare beneficiaries face higher healthcare costs due to these changes and cuts to federal subsidies.

Impact on Medicare Beneficiaries

• 💸 The legislation supported by Kennedy delays or exempts top-selling oncology drugs from price reform, costing taxpayers billions.
• 💔 This forces families into crushing debt or to forego life-saving care due to unaffordable medication.
• ✅ Kennedy's claim of a 5% premium reduction via a "program integrity bill" was seen as disconnected from the specific premium hikes faced by seniors.

Rhetoric vs. Reality

• 🎭 The exchange exposed a significant gap between Kennedy's populist rhetoric about fighting Big Pharma and the actual policy consequences of the legislation he supports.
• 🧠 His inability to answer basic questions suggested either a troubling lack of knowledge about his agency's core functions or an unwillingness to acknowledge contradictory policies.
• 🔍 Cortez Masto's questioning underscored the intensifying national debate over Medicare reform, prescription drug pricing, and healthcare affordability for seniors.